Premium
Autologous activated macrophages (MAK™) coated ex vivo with humanized anti‐CD20 monoclonal antibodies can eradicate minimal residual disease in chronic lymphocytic leukaemia in clinical response
Author(s) -
Sutton Laurent,
Chaoui Driss,
Cazin Bruno,
Azar Nabih,
Chokri Mohamed,
RometLemonne JeanLoup,
Maloum Karim
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07272.x
Subject(s) - fludarabine , minimal residual disease , medicine , rituximab , peripheral blood mononuclear cell , chronic lymphocytic leukemia , immunology , ighv@ , cd20 , cyclophosphamide , antibody , regimen , chemotherapy , oncology , leukemia , biology , in vitro , biochemistry